Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | GRK2 | P25098 | 2/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14720058 | 0.76 | P2RX7 (0.51) | POLBMAPTP2RX7NPC1AKR1A1 | |
| SCHEMBL2190433 | 0.76 | POLB (0.59) | ALDH1A1POLBGRK2CTDSP1L3MBTL1 | |
| SCHEMBL28420180 | 0.74 | ALDH1A1 (0.50) | ALDH1A1POLBGRK2CTDSP1L3MBTL1 | |
| SCHEMBL13485810 | 0.74 | MAPK8 (0.54) | ALDH1A1MAPK8SMN1; SMN2P2RX7 | |
| SCHEMBL16046822 | 0.73 | KMT2A (0.61) | ALDH1A1L3MBTL1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL25474855 | 0.72 | POLB (0.59) | ALDH1A1POLBGRK2CTDSP1L3MBTL1 | |
| SCHEMBL13018932 | 0.72 | SMN1; SMN2 (0.59) | ALDH1A1POLBGRK2CTDSP1L3MBTL1 | |
| SCHEMBL13652566 | 0.72 | POLB (0.59) | ALDH1A1POLBGRK2CTDSP1L3MBTL1 | |
| SCHEMBL29574729 | 0.72 | AKR1B1 (0.52) | P2RX7AKR1A1AKR1B1MEN1KMT2A | |
| SCHEMBL5835 | 0.72 | AKR1B1 (0.52) | P2RX7AKR1A1AKR1B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789100-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9789100-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9789100-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-17 | — | — | US | disclosed |
| EP-2970191-B1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970191-B1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-20160271123-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | US | disclosed |
| US-20160271123-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | US | disclosed |
| US-20160271123-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-09-22 | — | — | US | disclosed |
| US-9382238-B2 | Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-07-05 | — | — | US | disclosed |
| US-9382238-B2 | Pyridine derivatives as rearranged during transfection (RET) kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-07-05 | — | — | US | disclosed |
| US-20150099762-A1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-20150099762-A1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8937071-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-20 | — | — | US | disclosed |
| US-8937071-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-20 | — | — | US | disclosed |
| US-8937071-B2 | Compounds as rearranged during transfection (RET) inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-01-20 | — | — | US | disclosed |
| WO-2014141187-A1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014141187-A1 | PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099762-A1 | COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ALDH1A1 2176/4885POLB 4622/4885GRK2 68/4885 |
| US-20140275111-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ALDH1A1 2779/4885POLB 4687/4885GRK2 87/4885 |
| US-20160271123-A1 | NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS | RET, FER, THRB | ALDH1A1 2779/4885POLB 4687/4885GRK2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.